TITLE

COMMENTARY: Caspofungin was noninferior to amphotericin B for invasive fungal infections in persistent fever and neutropenia and was better tolerated

AUTHOR(S)
Glatt, Aaron E.
PUB. DATE
March 2005
SOURCE
ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that febrile neutropenia remains one of the most serious complications of cancer chemotherapy. Most patients require empiric treatment by algorithm to cover the most likely pathogens. Liposomal amphotericin B (AB) and fluconazole are no longer preferred as initial choices because of efficacy, resistance, and toxicity concerns. Many infectious disease specialists prefer liposomal AB, voriconazole, or CF as empiric regimens. The article states that caspofungin is noninferior to amphotericin B for invasive fungal infections in persistent fever and neutropenia.
ACCESSION #
16486568

 

Related Articles

  • Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Chan, Alexandre; Chen, Christy; Chiang, Joen; Tan, Sze; Ng, Raymond // Supportive Care in Cancer;Jul2012, Vol. 20 Issue 7, p1525 

    Objectives: The aim of this study was to investigate the incidence of febrile neutropenia (FN) with adjuvant AC (doxorubicin and cyclophosphamide) chemotherapy among Asian early-stage breast cancer (ESBC) patients, to evaluate the impact of FN on chemotherapy delivery, and to identify specific...

  • Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Ray-Coquard, I; Borg, C; Bachelot, Th; Sebban, C; Philip, I; Clapisson, G; Le Cesne, A; Biron, P; Chauvin, F; Blay, J Y // British Journal of Cancer;1/27/2003, Vol. 88 Issue 2, p181 

    A risk model for febrile neutropenia (FN) after conventional cytotoxic chemotherapy, based on early (day 5) lymphopenia and the dose of chemotherapy, has been described. A risk index based on parameters available at day I would be easier in daily practice. The objectives of this work were (I) to...

  • A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. M. Moreau; J. Klastersky; A. Schwarzbold; F. Muanza; A. Georgala; M. Aoun; A. Loizidou; M. Barette; S. Costantini; M. Delmelle; L. Dubreucq; M. Vekemans; A. Ferrant; D. Bron; M. Paesmans // Annals of Oncology;Mar2009, Vol. 20 Issue 3, p513 

    Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk...

  • A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. Bozcuk, H.; Yıldız, M.; Artaç, M.; Kocer, M.; Kaya, Ç.; Ulukal, E.; Ay, S.; Kılıç, M.; Şimşek, E.; Kılıçkaya, P.; Uçar, S.; Coskun, H.; Savas, B. // Supportive Care in Cancer;Jun2015, Vol. 23 Issue 6, p1759 

    Purpose: There is clinical need to predict risk of febrile neutropenia before a specific cycle of chemotherapy in cancer patients. Methods: Data on 3882 chemotherapy cycles in 1089 consecutive patients with lung, breast, and colon cancer from four teaching hospitals were used to construct a...

  • Life-Threatening Sepsis Associated With Adjuvant Doxorubicin Plus Docetaxel for Intermediate-Risk Breast Cancer. Brain, Etienne G. C.; Bachelot, Thomas; Serin, Daniel; Kirscher, Sylvie; Graic, Yvon; Eymard, Jean-Christophe; Extra, Jean-Marc; Combe, Martin; Fourme, Emmanuelle; Noguès, Catherine; Rouëssé, Jacques // JAMA: Journal of the American Medical Association;5/18/2005, Vol. 293 Issue 19, p2367 

    Context Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity. Objective To describe adverse events associated with adjuvant chemotherapy for breast cancer, which led to premature termination of a clinical trial. Design, Setting, and Patients We...

  • Management of febrile neutropenia: ESMO Clinical Recommendations. Marti, F. Marti; Cullen, M. H.; Roila, F. // Annals of Oncology;May2009 Supplement 4, Vol. 20, piv166 

    The article presents clinical recommendations for the management of febrile neutropenia from the European Society for Medical Oncology (ESMO). The disease is considered one of the most feared complications of cancer chemotherapy. Prompt recognition of, and reaction to, potential infection is a...

  • The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Klastersky, Jean; Paesmans, Marianne // Supportive Care in Cancer;May2013, Vol. 21 Issue 5, p1487 

    The Multinational Association for Supportive Care in Cancer risk index score developed, through a multinational collaboration, was published in 2000 with the aim to identify patients with chemotherapy-induced febrile neutropenia at low risk of serious medical complication development. It has...

  • Primary Care of the Patient with Cancer. Smith, George F.; Toonen, Timothy R. // American Family Physician;4/15/2007, Vol. 75 Issue 8, p1207 

    Care of patients with cancer can be enhanced by continued involvement of the primary care physician. The physician's role may include informing the patient of the diagnosis, helping with decisions about treatment, providing psychological support, treating intercurrent disease, continuing...

  • Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Ahn, Shin; Lee, Yoon-Seon; Chun, Yun-Hee; Kwon, In-Ho; Kim, Won; Lim, Kyung; Kim, Tae; Lee, Kyoo-Hyung // Supportive Care in Cancer;Aug2011, Vol. 19 Issue 8, p1151 

    Objectives: We intended to determine the predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia (FN). Methods: From January 1, 2007 to December 31, 2008, 396 episodes of FN in 346 cancer patients were retrospectively analyzed. Clinical and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics